Range of suitable individuals: CDEC talked about the uncertainty in the quantity of people with reasonably severe to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some individuals who are classified as having moderate or reasonable ailment could possibly have a critical